SEARCH:   Advanced

Blood, Vol. 108, Issue 7, 2332-2338, October 1, 2006 This Article Abstract Full Text Services Email this article to a friend Alert me to new issues of the journal Rights and Permissions Citing Articles Citing Articles via CrossRef Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)–based mutagenesis screen: high efficacy of drug combinations Blood Bradeen et al. 108: 2332 Supplemental materials for: Bradeen et al Files in this Data Supplement: Table S1. Time to detection of growth in the presence of kinase inhibitor (PDF, 51.8 KB) Table S2. Point mutants recovered with combinations of imatinib and nilotinib and imatinib and dasatinib (PDF, 57.6 KB) Table S3. Nucleotide substitutions representing BCR-ABL kinase domain mutations observed in ENU mutagenesis screen (PDF, 54.7 KB) - The first two columns represent the total number of mutations recovered with all 3 inhibitors and the second two columns represent mutations recovered in the presence of imatinib 2mM only, representing the experiment with the least bias towards T315I. This Article Abstract Full Text Services Email this article to a friend Alert me to new issues of the journal Rights and Permissions Citing Articles Citing Articles via CrossRef

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020